

## HR 3810

### Drug Origin Transparency Act of 2023

**Congress:** 118 (2023–2025, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jun 5, 2023

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Jun 9, 2023)

**Official Text:** <https://www.congress.gov/bill/118th-congress/house-bill/3810>

## Sponsor

**Name:** Rep. Eshoo, Anna G. [D-CA-16]

**Party:** Democratic • **State:** CA • **Chamber:** House

## Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Craig, Angie [D-MN-2]	D · MN		Jul 11, 2023
Rep. Sarbanes, John P. [D-MD-3]	D · MD		Jul 11, 2023
Rep. Peters, Scott H. [D-CA-50]	D · CA		Jul 25, 2023
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Sep 13, 2023

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 9, 2023

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
118 HR 4697	Related bill	Jul 21, 2023: Referred to the Subcommittee on Health.

## Summary (as of Jun 5, 2023)

### Drug Origin Transparency Act of 2023

This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.

Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

## **Actions Timeline**

---

- **Jun 9, 2023:** Referred to the Subcommittee on Health.
- **Jun 5, 2023:** Introduced in House
- **Jun 5, 2023:** Referred to the House Committee on Energy and Commerce.